Advancements in Cancer Treatment
The senior scientist discussed the efficacy of G12 inhibitors, explaining that although the development of the KRAS G12C inhibitor was “exciting”, it was unlikely to work as a monotherapy. Instead, the drug should be used in combination with other compounds. She noted that combination approaches should be used both upstream with epidermal growth factor receptor and downstream with mitogen-activated protein kinase or extracellular signal-regulated kinases to account for toxicity levels.
The specialist continued by sharing her views on Amgen and Mirati, specifically which of the two companies has a stronger product. Although she admitted that Mirati had a stronger G12C inhibitor as a result of its longer half-life, the senior scientist noted that Mirati’s product offering could face other concerns, which she outlined.
The specialist continued the conversation by outlining the role of Novartis and Eli Lilly. She explained that compared with Mirati and Amgen, who simply produced the “pioneer molecules”, Novartis and Eli Lilly could use the data provided by Mirati and Amgen to create rival inhibitors. The specialist concluded by explaining the risk of cancerous cells becoming resistant to inhibitors, as well as the risk of toxicity for KRAS G12C drugs.
To access all the human insights from Third Bridge’s KRAS G12C Inhibitors Interview, click below to view the full transcript.
Related Transcripts
The information used in compiling this document has been obtained by Third Bridge from experts participating in Forum Interviews. Third Bridge does not warrant the accuracy of the information and has not independently verified it. It should not be regarded as a trade recommendation or form the basis of any investment decision.
For any enquiries, please contact sales@thirdbridge.com
